Mar 10, 2025 8:30 am EDT New Findings Show how LIXTE’s Lead Clinical Compound, LB-100, is Metabolized to its Active Form
Feb 25, 2025 8:30 am EST LIXTE Adds Northwestern University’s Lurie Cancer Center as Second Site in Ongoing Clinical Trial for Ovarian Clear Cell Cancer
